23556-66-3

Basic information

• Product Name: N-alpha-carbobenzoxy-N-epsilon-t-butyloxycarbonyl-L-lysyl-N-epsilon-t-butyloxycarbonyl-L-lysine methyl ester
• Synonyms: N-alpha-carbobenzoxy-N-epsilon-t-butyloxycarbonyl-L-lysyl-N-epsilon-t-butyloxycarbonyl-L-lysine methyl ester
• CAS NO: 23556-66-3
• Molecular Weight: 622.759
• Mol File: 23556-66-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-alpha-carbobenzoxy-N-epsilon-t-butyloxycarbonyl-L-lysyl-N-epsilon-t-butyloxycarbonyl-L-lysine methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-alpha-carbobenzoxy-N-epsilon-t-butyloxycarbonyl-L-lysyl-N-epsilon-t-butyloxycarbonyl-L-lysine methyl ester(23556-66-3)
• EPA Substance Registry System: N-alpha-carbobenzoxy-N-epsilon-t-butyloxycarbonyl-L-lysyl-N-epsilon-t-butyloxycarbonyl-L-lysine methyl ester(23556-66-3)

Safety Data

• Hazardous Substances Data: 23556-66-3(Hazardous Substances Data)

Upstream product

• 3017-32-1 (S)-methyl 2-amino-6-(tert-butoxycarbonylamino)hexanoate 
• 2389-60-8 Z-Lys(Boc)-OH 
• 2389-48-2 N-ε-tert-butoxycarbonyl-L-lysine methyl ester hydrochloride 

Downstream Products

• 52068-17-4 N-alpha-carbobenzoxy-N-epsilon-t-butyloxycarbonyl-L-lysyl-N-epsilon-t-butoxycarbonyl-L-lysyl-N-epsilon-t-butyloxycarbonyl-L-lysine methyl ester 
• 87219-44-1 N-alpha-carbobenzoxy-N-epsilon-t-butyloxycarbonyl-L-lysyl-N-epsilon-t-butyloxycarbonyl-L-lysyl-N-epsilon-t-butyloxycarbonyl-L-lysyl-N-epsilon-t-butyloxycarbonyl-L-lysine methyl ester 
• 47846-88-8 Z-L-Lys(Boc)-L-Lys(Boc)-OH 
• 22897-22-9 Z-Lys(Boc)-Lys(Boc)-NH-NH₂ 

Relevant articles and documents

Chloride-Assisted Peptide Macrocyclization

The role of the Cl- anion as a templating agent for the synthesis of cyclopeptides was assessed through the preparation of three new homocyclolysines and other six cyclic peptides by head-to-tail lactamization. Isolated yields of products obtai

LIGAND-TARGETED MOLECULES AND METHODS THEREOF

The present invention relates to ligand-targeted molecules and ligand drug conjugates (LDCs) comprising a ligand connected to a functional group, which is connected to a linker, which in turn is bonded to a drug. The LDCs of the present invention also comprise platinum coordination complex wherein the platinum is connected to the linker through monocarboxylato and O→Pt coordinate bonds. The present invention also relates to methods for preparing these ligand drug conjugates. The present invention further relates to methods for the treatment of tumours using the ligand drug conjugates of the present invention.